←back to Blog

Эвалар — лидер среди БАДов

Производство биологически активных добавок для здоровья.

←Назад: Meet Open-Qwen2VL: A Fully Open and Compute-Efficient Multimodal Large Language Model

Далее: First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial→